Detailed Chinese instructions for Adagrasib

[drug name]

Common name: adaglasib

English name:Adagrasib

Commodity name:Krazati (commodity name in some regions)

Drug type: anti-tumor targeted drugs

[Ingredients and properties]

The main ingredient is adagrasib, a KRAS G12C mutation inhibitor. Medications are taken as oral preparations, usually as tablets or capsules, and the color may vary slightly from manufacturer to manufacturer.

【Indications】

Adagrasiib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations, particularly those whose disease has progressed despite at least one prior systemic therapy. Studies have shown that the KRAS G12C mutation plays an important pathogenic role in some non-small cell lung cancer and other cancer types, and adagrasib exerts an anti-cancer effect by inhibiting the activity of the mutant protein.

【Usage and Dosage】

The recommended dose is 600mg twice daily (i.e., the total daily dose is 1200mg), administered orally. The medicine should be swallowed whole and not crushed or chewed. It can be taken before or after meals, but the medication time should be kept regular. Treatment should be continued until the disease progresses significantly or intolerable toxicity occurs. Doctors can adjust the dosage appropriately based on the patient's individual tolerance.

【Adverse reactions】

Common adverse reactions observed in clinical studies include:

Gastrointestinal symptoms: diarrhea, nausea, vomiting, constipation

Fatigue and decreased appetite

Abnormal liver function (elevated transaminases)

Elevated creatinine

Pulmonary toxicity (rare but potentially serious)

Some patients may experience ECG abnormalities such as QT prolongation and electrolyte imbalance, and should be checked regularly during treatment. Most side effects are mild to moderate and can be alleviated by dose adjustment or symptomatic treatment.

【Taboo】

It is forbidden for those who are allergic to the active ingredient of adagrasibu or any excipients.

It is prohibited for pregnant and lactating women because animal experiments have shown potential toxic effects on the fetus.

It is not recommendedfor patients under the age of 18 as there is insufficient clinical data for this group.

【Notes】

Liver function monitoring: Liver function should be checked regularly during medication, especially ALT, AST and bilirubin levels. Abnormalities should be dealt with promptly or medication should be suspended.

Drug interactions: Avoid coadministration with strongCYP3A4 inhibitors or inducers (such as ketoconazole, rifampicin) to prevent the metabolic rate from being affected, resulting in toxicity or reduced efficacy.

QTRisk of prolongation of QT: Patients with a history of abnormal heart rhythms should evaluate their heart health before using adagrasib and conduct regular electrocardiograms if necessary.

Pregnancy and contraception: Women of childbearing age should take effective contraceptive measures during treatment and for at least 4 weeks after stopping the drug; male patients also need to continue contraception for more than 3 months after stopping the drug.

【Drug Storage】

Please keep this product in a cool and dry place (usually recommended not to exceed 25℃), avoid direct sunlight and high temperature and humidity, and keep it away from the reach of children.

[Listing and purchasing instructions]

As of2025, adagrasib has not been approved for marketing in mainland China and cannot be purchased directly through domestic pharmacies. Original drugs or generic drugs need to be obtained through overseas channels. The price of original drugs in the United States is relatively high, and the monthly treatment cost is as high as hundreds of thousands of yuan. Counterfeit versions have been released in countries such as Laos. The price is about more than 3,000 yuan per box. The ingredients are basically the same as the original drug and are more economical. However, patients should consult a doctor and obtain drugs through formal channels when choosing.

【Manufacturer】

The original drug of adagrasibu is developed and produced by the American company Mirati Therapeutics.

References：https://www.krazati.com/